The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...
Arrowhead Pharmaceuticals has seen its consensus analyst price target increase from $45 to $47.50 per share, reflecting growing confidence in the company's strategy and market positioning. This ...
Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...
Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet ...
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII ...
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback